drugset
drugset / Trial / NCT01003405

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

NCT01003405 ↗

Phase 3 Withdrawn 100 enrolled Kissei Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritobegron Small molecule — —

Indications

overactive bladder